Roche buys AI-powered diagnostics player PathAI
Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy the company outright for $1.05 billion.
Already a giant in the diagnostics space, the Swiss group is hoping to take control of PathAI's Image Management System (IMS) platform, which they have been working on together since 2021 and combines PathAI's image analysis algorithms with Roche's Navify digital pathology platform.
The alliance was expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms, used to help match a patient to a specific drug or therapy, that can be integrated into pathology laboratory workflows.
Now, Roche wants to fold PathAI into its diagnostics division, which contributed around 22% of the group's total 2025 revenues of $79 billion and is the largest player in the global diagnostics market.
"Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens," said Matt Sause, Roche Diagnostics' chief executive, in a statement this morning.
"Bringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better outcomes for patients worldwide," he added.
The pharma group has agreed to pay $750 million upfront for Boston, Massachusetts-based PathAI, with another $300 million in milestone payments.
It also said that buying PathAI will strengthen its biopharma services business, as PathAI's platform can also be used to support clinical trials and translational research studies.
Like most big pharma groups, Roche has been ramping up its investments in AI infrastructure and capabilities in recent years, and in March expanded an alliance with NVIDIA to embed AI across its operations, from discovery to development, manufacturing, and commercialisation.
The merger is subject to the usual closing conditions, including antitrust and regulatory approvals, and is currently expected in the second half of the year, according to Roche.
More information on the acquisition will likely be available at Roche's Diagnostics Day event, which is due to be held next week in London, UK.
PathAI CEO, Andy Beck, said that joining forces with Roche "marks a new era for PathAI, enabling us to realise our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed. Roche's global infrastructure and expertise will bring our digital diagnostics technology to patients worldwide."
